Forte Biosciences director exercises 1,250 shares

Forte Biosciences director and officer Paul A. Wagner reported routine equity compensation activity.

Rhea-AI Filing Summary

Forte Biosciences director and officer Paul A. Wagner reported routine equity compensation activity. On July 1, 2026, he exercised restricted stock units to acquire 1,250 shares of Common Stock at a conversion price of $0.00 per share.

To cover tax obligations, 98 shares of Common Stock were disposed of in a tax-withholding transaction at $21.32 per share, which is not an open-market sale. After these transactions, Wagner directly owned 85,482 shares of Common Stock and 2,500 Restricted Stock Units, each RSU representing a contingent right to receive one share, subject to continued service and quarterly vesting under the 2021 Equity Incentive Plan.

Insider Trade Summary

1,250 shares exercised/converted

Exercise 3 txns

Insider Wagner Paul A.

Role SEE REMARKS

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,250	$0.00	$0.00
Exercise	Common Stock	1,250	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	98	$21.32	$2K

Holdings After Transaction: Restricted Stock Units — 2,500 contracts (Direct); Common Stock — 85,482 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
2. F2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

Key Figures

RSU exercise: 1,250 shares Tax-withholding shares: 98 shares Post-transaction holdings: 85,482 shares +3 more

6 metrics

RSU exercise 1,250 shares Common Stock acquired on July 1, 2026 via RSU conversion

Tax-withholding shares 98 shares Common Stock disposed of at $21.32 per share for taxes

Post-transaction holdings 85,482 shares Common Stock directly owned after transactions

Remaining RSUs 2,500 units Restricted Stock Units outstanding after the reported exercise

Tax-withholding price $21.32 per share Value used for 98-share tax-withholding disposition

RSU conversion price $0.00 per share Exercise or conversion price for RSUs into Common Stock

Key Terms

Restricted Stock Units, tax-withholding disposition, derivative security, Quarterly Vesting Date, +1 more

5 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax-withholding disposition financial

"Payment of exercise price or tax liability by delivering securities"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Quarterly Vesting Date financial

"one-sixteenth (1/16th) of the RSUs...shall vest on each Quarterly Vesting Date"

2021 Equity Incentive Plan financial

"Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did FBRX’s Paul A. Wagner report?

Paul A. Wagner reported exercising 1,250 restricted stock units into Forte Biosciences Common Stock and a related tax-withholding share disposition. These actions reflect equity compensation mechanics, not open-market buying or selling of existing holdings.

Did the FBRX insider sell shares on the open market in this Form 4?

No open-market sale was reported. Instead, 98 shares of Common Stock were disposed of to satisfy tax obligations related to the RSU exercise, a standard tax-withholding mechanism rather than a discretionary market sale.

How many Forte Biosciences shares does Paul A. Wagner hold after the transactions?

Following the reported transactions, Paul A. Wagner directly holds 85,482 shares of Forte Biosciences Common Stock. He also holds 2,500 Restricted Stock Units, which may convert into additional shares as they vest over time.

What does the 1,250-share RSU exercise mean for FBRX?

The 1,250-share RSU exercise represents equity compensation converting into Forte Biosciences Common Stock at a $0.00 conversion price. It increases Wagner’s share ownership while slightly expanding the share count through the issuance of new shares under the incentive plan.

How do the Restricted Stock Units for FBRX vest over time?

Each Restricted Stock Unit represents a right to receive one Forte Biosciences share. Vesting occurs in 1/16th increments on Quarterly Vesting Dates—January 1, April 1, July 1, and October 1—if the reporting person remains a service provider.

What is the purpose of the 98-share tax-withholding transaction in the FBRX filing?

The 98-share tax-withholding disposition covers tax liabilities associated with the RSU exercise. Instead of paying cash taxes, a portion of newly acquired shares is delivered to satisfy obligations, leaving the insider with a net increase in holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wagner Paul A.

(Last) (First) (Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BLDG 6

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		M		1,250	A	(1)	85,580	D
Common Stock	07/01/2026		F		98	D	$21.32	85,482	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	07/01/2026		M			1,250	(2)	(2)	Common Stock	1,250	$0	2,500	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

Remarks:

CEO, Secretary and Chair of the Board

	/s/ Paul A. Wagner, Ph.D.	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)